Fiche publication
Date publication
janvier 2012
Journal
Cytometry. Part A : the journal of the International Society for Analytical Cytology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr DECONINCK Eric
,
Dr FERRAND Christophe
,
Pr GARNACHE-OTTOU Francine
,
Dr LAROSA Fabrice
,
Dr LEGRAND Fabien
,
Pr SEILLES Estelle
,
Dr ANGELOT-DELETTRE Fanny
Tous les auteurs :
Solly F, Angelot F, Garand R, Ferrand C, Seillès E, Schillinger F, Decobecq A, Billot M, Larosa F, Plouvier E, Deconinck E, Legrand F, Saas P, Rohrlich PS, Garnache-Ottou F
Lien Pubmed
Résumé
Minimal residual disease (MRD) has emerged as a major prognostic factor for monitoring patients with B-lineage acute lymphoblastic leukemia (B-ALL). The quantification of MRD by flow cytometry (FC) is based on the identification of a leukemia-associated phenotype (LAP). Because phenotypic switch is common during treatment, multiple LAPs must be available and used for MRD detection over time. We evaluated the potential usefulness of CD304 as a new marker for monitoring MRD. CD304 was expressed in 48% of B-ALL (24/50) with discriminative fluorescence intensity compared with CD304-negative normal B-cell precursors (n = 15). The sensitivity of CD304-based MRD detection reached 10(-4), as with some of established LAPs. The stability of CD304 expression evaluated during therapy and at relapse confirms the usefulness of this marker for MRD quantification. Finally, CD304 was repeatedly expressed in patients with TEL-AML1 gene rearrangement, which warrants further investigation on its potential relevance as a prognosis marker or therapeutic target.
Mots clés
Adolescent, Adult, B-Lymphocytes, immunology, Biomarkers, metabolism, Cell Lineage, Core Binding Factor Alpha 2 Subunit, genetics, Female, Flow Cytometry, methods, Gene Rearrangement, Humans, Male, Middle Aged, Neoplasm, Residual, diagnosis, Neuropilin-1, immunology, Oncogene Proteins, Fusion, genetics, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, genetics, Young Adult
Référence
Cytometry A. 2012 Jan;81(1):17-24
